Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2019 | Story Valentino Ndaba | Photo Johan Roux
Dr Thandi
After nearly seven years Dr Lewin finally graduates with a PhD.

Dr Thandi Lewin has spent the past six-and-a-half years of her life on her PhD.  It was only in the final year of the process that the thesis came together. “I had a few chapters and had done literature reviews and some theoretical work, as well as a little initial analysis, but none of it actually added up to a coherent thesis. The moment when I realised that I actually did have a thesis was a great feeling and a huge relief because it was only then that the end was in sight,” she said. 

On Wednesday 11 December 2019 her diligence culminated in a graduation ceremony at which she obtained her PhD in Higher Education Studies in the Faculty of Education at the University of the Free State (UFS). Dr Lewin formed a part of the pioneering cohort of the South African Research Chairs Initiative (SARChI) Chair in Higher Education and Human Development Research Programme, under the leadership of Professor Melanie Walker

Through the twists and turns

Working on her thesis on Early career women academics: A case study of working lives in a gendered institution, Dr Lewin struggled with time constraints. “I could not work on it every night or every early morning like some people do. My job was demanding, so I worked most nights and often went to bed quite late. Hence, I failed to focus on it during the week,” she explained.

When she began her PhD her youngest child was one year old. In addition to her job becoming more and more challenging over the years, Dr Lewin also had to maintain a morning and evening routine in order to make the most of the limited time she and her family had together. Yet after all was said and done, her research still beckoned.

Reaching the stage of walking across the stage

Given the rigorous process of completing a PhD, one of the major motivators was her supervisor. “Prof Walker was loyal and never gave up on me. She was also pragmatic and understanding. The commitment from a supervisor who is considerate of your personal circumstances, but is also as dedicated to your research project as you are, is quite something to find.”

For much of the past three years of her doctorate, Dr Lewin’s father was ill. He eventually succumbed to his illness in January 2019. The graduate struggled with managing her emotions as she felt guilty about not spending enough time with him due to work and research. “Being a mum and a daughter meant that if I wasn’t at work or working on my PhD I was with my kids or with my dad. But I must also acknowledge that my partner, nanny, and part-time housekeeper provided critical support which I couldn’t have done without.”

On gender and organisational cultures

The Chief Director for Institutional Governance and Management support in the university education branch of the Department of Higher Education and Training found the experience garnered in the system-level of higher learning enormously helpful in her research process.   “I have really enjoyed working in an area that interests me, and engaging with a topic that is policy-relevant,” she said.

Content
Melanie Walker (right) reading the PhD appraisal for Dr Thandi Lewin at the Graduation Ceremony.
(Photo: Johan Roux)


Cultivating culture change

Enabling women to rise through the ranks would require more effort to improve gender equity. “Organisations and universities can never really achieve gender equity without fundamentally changing their structures and cultures, which are deeply gendered. This also cannot happen without social change, which needs to take place in broader society and not only within organisations,” said Dr Lewin.

What this means for society and organisations is a shift from focusing solely on individual women. According to Dr Lewin: “Universities, in addition to their inclination towards slow change, are also experienced by many as exclusionary – not just by women, but by people of colour and those from working-class backgrounds, and others who have been traditionally marginalised in higher education. This is a critical issue for South African higher education – it is going to take a lot of time and focused commitment to change the cultures of universities to be more inclusive.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept